Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

MediciNova stock

MNOV
US58468P2065
A0LF3U

Price

1.53
Today +/-
-0.04
Today %
-2.58 %
P

MediciNova stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the MediciNova stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the MediciNova stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the MediciNova stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze MediciNova's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

MediciNova Stock Price History

DateMediciNova Price
11/8/20241.53 undefined
11/7/20241.57 undefined
11/6/20241.56 undefined
11/5/20241.61 undefined
11/4/20241.68 undefined
11/1/20241.66 undefined
10/31/20241.68 undefined
10/30/20241.75 undefined
10/29/20241.75 undefined
10/28/20241.63 undefined
10/25/20241.66 undefined
10/24/20241.73 undefined
10/23/20241.73 undefined
10/22/20241.81 undefined
10/21/20241.78 undefined
10/18/20241.81 undefined
10/17/20241.81 undefined
10/16/20241.85 undefined
10/15/20241.81 undefined
10/14/20241.77 undefined
10/11/20241.78 undefined
10/10/20241.97 undefined

MediciNova Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into MediciNova, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by MediciNova from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects MediciNova’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of MediciNova. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into MediciNova’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing MediciNova’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on MediciNova’s growth potential.

MediciNova Revenue, EBIT and net profit per share

DateMediciNova RevenueMediciNova EBITMediciNova Net Income
2026e0 undefined-12.34 M undefined-12.01 M undefined
2025e0 undefined-11.93 M undefined-12.01 M undefined
2024e0 undefined-12.24 M undefined-11.51 M undefined
20231 M undefined-9.9 M undefined-8.57 M undefined
20220 undefined-14.63 M undefined-14.07 M undefined
20214.04 M undefined-10.22 M undefined-10.13 M undefined
20200 undefined-14.18 M undefined-13.85 M undefined
20190 undefined-14.03 M undefined-12.94 M undefined
20180 undefined-15.59 M undefined-14.68 M undefined
20170 undefined-13.03 M undefined-11.16 M undefined
20160 undefined-10.88 M undefined-10.87 M undefined
20150 undefined-8.82 M undefined-8.85 M undefined
20140 undefined-9.22 M undefined-9.2 M undefined
20136 M undefined-4.02 M undefined-4.03 M undefined
2012800,000 undefined-10.95 M undefined-10.96 M undefined
20110 undefined-16.11 M undefined-17.73 M undefined
20100 undefined-17.88 M undefined-20.19 M undefined
20090 undefined-21.24 M undefined-20.37 M undefined
20080 undefined-22.6 M undefined-21.92 M undefined
20070 undefined-53.49 M undefined-48.9 M undefined
2006260,000 undefined-41.68 M undefined-35.69 M undefined
2005800,000 undefined-30.09 M undefined-25.71 M undefined
2004490,000 undefined-48.61 M undefined-79.62 M undefined

MediciNova Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
0000000000060000000401000
-------------------------
-------------------------
0000000000000000000000000
-7-6-48-30-41-53-22-21-17-16-10-4-9-8-10-13-15-14-14-10-14-9-12-11-12
------------66.67--------250.00--900.00---
-6-6-79-25-35-48-21-20-20-17-10-4-9-8-10-11-14-12-13-10-14-8-11-12-12
--1,216.67-68.3540.0037.14-56.25-4.76--15.00-41.18-60.00125.00-11.1125.0010.0027.27-14.298.33-23.0840.00-42.8637.509.09-
0.050.050.058.9310.1311.7512.0712.1112.4114.8116.5220.724.0726.5832.9935.1441.1243.1644.4148.649.0549.05000
-------------------------
Details

Keystats

ⓘ

Revenue and Growth

The MediciNova Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the MediciNova is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                         
5.550.8138.7104.170.619.346.128.315.146.711.722.124.12862.363.86071.458.551
000000000060000000000
000000000000000000000
000000000000000000000
0.10.52.66.62.40.70.930.10.60.41.70.50.60.60.30.40.50.70.60.50.17
5.651.3141.3110.773204758.415.74.414.412.222.724.728.362.764.360.7725951.17
00.31.10.90.70.40.20.100.10.1000.10.10.10.40.10.90.70.62
00000242.100.70.70.70.70.70.60.6000000
000000000000000000000
0000004.84.84.84.84.84.84.84.84.84.84.84.84.84.84.8
0000009.19.69.69.69.69.69.69.69.69.69.69.69.69.69.6
02.200.105.831.20.100000.10000.10.20.10.10.07
02.51.110.730.247.414.615.115.215.215.115.215.115.114.514.914.715.415.215.1
5.653.8142.4111.773.750.294.47330.819.629.627.337.939.843.477.279.275.487.474.266.27
                                         
043.50000000000000000000.05
19.7103.6257258.6273.2276.4288.7293.5310312.3326.9332.7352.3364.9380.2429.3444454.3476.8477.4478.15
-15.1-94.8-120.5-156.2-205.1-227-247.4-267.5-285.3-296.2-301.4-310.6-319.4-330.3-341.5-356.1-369.1-382.9-393.1-407.1-415.7
0-1.2-0.80-0.10-0.1-0.1-0.1-0.1-0.1-0.1-0.1-0.1-0.1-0.1-0.1-0.1-0.1-0.1-0.12
000000000000000000000
4.651.1135.7102.46849.441.225.924.61625.42232.834.538.673.174.871.383.670.262.38
0.30.51.43.82.90.41.31.10.70.500.50.20.41.50.60.50.60.40.41
0.42.15.26.74.21.82.41.52.10.50.41.11.31.31.41.61.81.62.42.82.28
0000001.10.60.9000000000000
000000028.60000000000000
00000017.650000000000000
0.72.66.610.57.12.222.436.83.710.41.61.51.72.92.22.32.22.83.23.28
00000029.39.50000000000000
000000222222220.20.20.20.20.20.20.2
0.300.10000.701.61.71.71.71.71.71.71.71.91.70.70.50.41
0.300.10003211.53.63.73.73.73.73.71.91.92.11.90.90.70.61
12.66.710.57.12.254.448.37.34.74.15.35.25.44.84.14.44.13.73.93.89
5.653.7142.4112.975.151.695.674.231.920.729.527.33839.943.477.279.275.487.374.166.27
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of MediciNova provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand MediciNova's financial health and stability.

Assets

MediciNova's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that MediciNova must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of MediciNova after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into MediciNova's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-6-6-48-25-35-48-21-20-20-17-10-4-9-8-10-11-14-12-13-10-14-8
0000000000000000000000
000000000000000-1000000
000300-31-120-78001000-100
003401364530234781286311
000000001,0001,000000000000000
0000000000000000000000
-6-5-13-22-34-43-21-17-17-13-11-100-7-6-6-9-9-10-9-12-7
0000000000000000000000
0-1-11-8954321-12700000000000-4039
0-1-10-8864421-12700000000000-4039
0000000000000000000000
000000017-1-9000000000000
0960110-1100009113417810421072000
0959110-11001800113417810421072000
---1.00-------------------
0000000000000000000000
-6234-1-2910009-13-11241023341-311-5232
-6.78-5.94-13.87-23.86-34.27-44.24-21.12-17.03-17.72-13.32-11.94-10.690.82-7.15-6.63-6.92-9.12-9.13-10.87-9.41-12.92-7.45
0000000000000000000000

MediciNova stock margins

The MediciNova margin analysis displays the gross margin, EBIT margin, as well as the profit margin of MediciNova. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for MediciNova.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the MediciNova's sales revenue. A higher gross margin percentage indicates that the MediciNova retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the MediciNova's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the MediciNova's total revenue generated. When comparing the revenue margin year over year, investors can gauge the MediciNova's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the MediciNova. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the MediciNova's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

MediciNova Margin History

MediciNova Gross marginMediciNova Profit marginMediciNova EBIT marginMediciNova Profit margin
2026e100 %0 %0 %
2025e100 %0 %0 %
2024e100 %0 %0 %
2023100 %-990.03 %-857.15 %
2022100 %0 %0 %
2021100 %-252.97 %-250.74 %
2020100 %0 %0 %
2019100 %0 %0 %
2018100 %0 %0 %
2017100 %0 %0 %
2016100 %0 %0 %
2015100 %0 %0 %
2014100 %0 %0 %
2013100 %-67 %-67.17 %
2012100 %-1,368.75 %-1,370 %
2011100 %0 %0 %
2010100 %0 %0 %
2009100 %0 %0 %
2008100 %0 %0 %
2007100 %0 %0 %
200646.15 %-16,030.77 %-13,726.92 %
200516.25 %-3,761.25 %-3,213.75 %
200410.2 %-9,920.41 %-16,248.98 %

MediciNova Stock Sales Revenue, EBIT, Earnings per Share

The MediciNova earnings per share therefore indicates how much revenue MediciNova has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue MediciNova earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates MediciNova's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of MediciNova’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating MediciNova's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

MediciNova Revenue, EBIT and net profit per share

DateMediciNova Sales per ShareMediciNova EBIT per shareMediciNova Earnings per Share
2026e0 undefined0 undefined-0.24 undefined
2025e0 undefined0 undefined-0.24 undefined
2024e0 undefined0 undefined-0.23 undefined
20230.02 undefined-0.2 undefined-0.17 undefined
20220 undefined-0.3 undefined-0.29 undefined
20210.08 undefined-0.21 undefined-0.21 undefined
20200 undefined-0.32 undefined-0.31 undefined
20190 undefined-0.33 undefined-0.3 undefined
20180 undefined-0.38 undefined-0.36 undefined
20170 undefined-0.37 undefined-0.32 undefined
20160 undefined-0.33 undefined-0.33 undefined
20150 undefined-0.33 undefined-0.33 undefined
20140 undefined-0.38 undefined-0.38 undefined
20130.29 undefined-0.19 undefined-0.19 undefined
20120.05 undefined-0.66 undefined-0.66 undefined
20110 undefined-1.09 undefined-1.2 undefined
20100 undefined-1.44 undefined-1.63 undefined
20090 undefined-1.75 undefined-1.68 undefined
20080 undefined-1.87 undefined-1.82 undefined
20070 undefined-4.55 undefined-4.16 undefined
20060.03 undefined-4.11 undefined-3.52 undefined
20050.09 undefined-3.37 undefined-2.88 undefined
20049.8 undefined-972.2 undefined-1,592.4 undefined

MediciNova business model

MediciNova Inc is a biopharmaceutical company based in San Diego, California. The company is dedicated to developing innovative therapies for various diseases. MediciNova was founded in 2000 and has since become a leading company in the industry. MediciNova is one of the most popular companies on Eulerpool.com.

MediciNova SWOT Analysis

Strengths

MediciNova Inc possesses several strengths that contribute to its competitive advantage in the market. These strengths include:

  • Strong Research and Development (R&D) capabilities leading to innovative drug development.
  • Diverse pipeline with potential drugs in various stages of development.
  • Strong financial position with sufficient resources to support ongoing R&D activities.
  • Strategic partnerships with reputable pharmaceutical companies, providing access to additional resources and expertise.
  • Established reputation for delivering high-quality pharmaceutical products.

Weaknesses

Despite MediciNova Inc's strengths, the company also faces certain weaknesses that could hinder its growth and success. These weaknesses include:

  • Reliance on a limited number of drug candidates, increasing the risk of failure in clinical trials.
  • Limited marketing and commercialization capabilities, potentially affecting the successful launch of new drugs.
  • Vulnerability to changes in industry regulations, impacting the company's operations and profitability.
  • Risk of intellectual property infringement and legal challenges from competitors.
  • Possible difficulties in attracting and retaining top talent in the highly competitive pharmaceutical industry.

Opportunities

MediciNova Inc can capitalize on various opportunities in the market to further enhance its business prospects. These opportunities include:

  • Increasing global demand for innovative pharmaceuticals presents opportunities for market expansion.
  • Growing prevalence of certain diseases, providing a larger patient population for potential drug sales.
  • Advancements in technology and scientific research supporting the development of new drugs and treatment methods.
  • Potential collaborations with academic institutions for further research and product development.
  • Expansion into emerging markets with promising growth potential.

Threats

MediciNova Inc faces certain threats that could adversely affect its performance and market position. These threats include:

  • Intense competition from other pharmaceutical companies, resulting in potential pricing pressures and reduced market share.
  • Stringent regulatory requirements and approval processes for new drugs, leading to delays and increased costs.
  • Risk of generic substitution and patent expirations, impacting the company's revenue and profit margins.
  • Economic uncertainties and changes in healthcare policies affecting the affordability and accessibility of pharmaceutical products.
  • Potential negative impact of adverse events or safety concerns related to MediciNova Inc's drugs.

MediciNova Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

MediciNova historical P/E ratio, EBIT multiple, and P/S ratio

MediciNova shares outstanding

The number of shares was MediciNova in 2023 — This indicates how many shares 49.046 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue MediciNova earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates MediciNova's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of MediciNova’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating MediciNova's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for MediciNova.

MediciNova latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.06 -0.05  (18.3 %)2024 Q2
3/31/2024-0.05 -0.06  (-17.65 %)2024 Q1
12/31/2023-0.08 -0.04  (50.98 %)2023 Q4
9/30/2023-0.08 -0.01  (87.75 %)2023 Q3
6/30/2023-0.07 -0.06  (15.97 %)2023 Q2
3/31/2023-0.07 -0.07  (1.96 %)2023 Q1
12/31/2022-0.09 -0.06  (30.8 %)2022 Q4
9/30/2022-0.09 -0.07  (23.75 %)2022 Q3
6/30/2022-0.09 -0.08  (9.5 %)2022 Q2
12/31/2021-0.1 -0.04  (57.98 %)2021 Q4
1
2
3
4
5
...
7

Eulerpool ESG Scorecard© for the MediciNova stock

Eulerpool World ESG Rating (EESG©)

34/ 100

🌱 Environment

35

👫 Social

43

🏛️ Governance

23

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

MediciNova shareholders

%
Name
Stocks
Change
Date
11.21722 % 3D Investment Partners Pte. Ltd5,502,04704/17/2024
2.25472 % EW Healthcare Partners1,105,94106/30/2024
2.22616 % Iwaki (Yuichi)1,091,933207,5414/17/2024
1.39702 % BlackRock Institutional Trust Company, N.A.685,236-2,8436/30/2024
1.27081 % The Vanguard Group, Inc.623,33306/30/2024
0.93530 % Geode Capital Management, L.L.C.458,76520,9056/30/2024
0.91327 % Citi Investment Research (US)447,95706/30/2024
0.65850 % Matsuda (Kazuko)322,99604/17/2024
0.42813 % Renaissance Technologies LLC210,000-20,4006/30/2024
0.32049 % State Street Global Advisors (US)157,19806/30/2024
1
2
3
4
5
...
7

MediciNova Executives and Management Board

Dr. Yuichi Iwaki(73)
MediciNova President, Chief Executive Officer, Director (since 2000)
Compensation 1.29 M
Dr. Kazuko Matsuda(57)
MediciNova Chief Medical Officer, Director (since 2011)
Compensation 882,487
Mr. Geoffrey O'brien(54)
MediciNova Vice President
Compensation 611,887
Ms. Carolyn Beaver(65)
MediciNova Independent Director
Compensation 72,932
Mr. Hideki Nagao(66)
MediciNova Independent Director
Compensation 72,932
1
2

Most common questions regarding MediciNova

What values and corporate philosophy does MediciNova represent?

MediciNova Inc represents a commitment to developing innovative and effective treatments for life-threatening diseases. With a strong focus on research and development, the company aims to improve patients' lives by addressing unmet medical needs. MediciNova adopts a patient-centric approach, ensuring that the interests and well-being of patients remain at the forefront of their operations. The company values scientific excellence, collaboration, and integrity in its pursuit of advancing healthcare solutions. By leveraging cutting-edge technologies and strategic partnerships, MediciNova strives to make a positive impact in the field of medicine, demonstrating its dedication to improving global health outcomes.

In which countries and regions is MediciNova primarily present?

MediciNova Inc is primarily present in the United States.

What significant milestones has the company MediciNova achieved?

MediciNova Inc has achieved significant milestones in its history. One notable accomplishment is the FDA approval of their lead product candidate, MN-166. This drug has shown promising results in clinical trials for multiple sclerosis and amyotrophic lateral sclerosis. Furthermore, MediciNova Inc has successfully completed several strategic collaborations and partnerships, including a licensing agreement with Kyowa Kirin for MN-166 in certain territories. This collaboration has provided the company with additional resources and expertise to further develop and commercialize their innovative treatments. Moreover, MediciNova Inc has made progress in expanding their pipeline by advancing other drug candidates, such as MN-001 and MN-221, in various clinical programs.

What is the history and background of the company MediciNova?

MediciNova Inc. is a renowned biopharmaceutical company that specializes in the development and commercialization of innovative therapies for various diseases. Established in 2000, MediciNova focuses on the acquisition and advancement of promising medical compounds. The company is committed to enhancing patients' lives by targeting unmet medical needs in neurology, respiratory, and oncology fields. MediciNova's extensive research efforts have contributed to the development of potential breakthrough therapies, including its lead compound, MN-166 (ibudilast), used in the treatment of progressive multiple sclerosis and amyotrophic lateral sclerosis. MediciNova Inc. continues to pioneer advancements in the healthcare industry, striving to make a positive impact on patients' lives worldwide.

Who are the main competitors of MediciNova in the market?

The main competitors of MediciNova Inc in the market are pharmaceutical companies such as Novartis, Pfizer, Johnson & Johnson, and Roche.

In which industries is MediciNova primarily active?

MediciNova Inc primarily operates in the biotechnology industry.

What is the business model of MediciNova?

The business model of MediciNova Inc focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of various diseases. With a strategic emphasis on the development of small molecule drugs, MediciNova aims to address unmet medical needs in areas such as neurology, oncology, inflammatory disorders, and respiratory diseases. By leveraging their expertise in drug development, MediciNova seeks to deliver innovative and effective treatment options to improve patient outcomes. Through their dedication to research and development, MediciNova Inc strives to advance healthcare by bringing new therapeutic solutions to the market.

What is the P/E ratio of MediciNova 2024?

The MediciNova P/E ratio is -6.52.

What is the P/S ratio of MediciNova 2024?

The MediciNova P/S ratio is 0.

What is the Quality Investing of MediciNova?

The Quality Investing for MediciNova is 2/10.

What is the revenue of MediciNova 2024?

The revenue cannot currently be calculated for MediciNova.

How high is the profit of MediciNova 2024?

The expected MediciNova profit is -11.51 M USD.

What is the business model of MediciNova

MediciNova Inc. is a biopharmaceutical company focused on the development of therapeutic drugs for unmet medical needs. It was founded in 2000 and is headquartered in San Diego, California. The business model of MediciNova Inc. is based on the discovery of new compounds and therapies for the treatment of diseases that are currently not adequately treated. The company primarily focuses on neurological and inflammatory diseases, as well as respiratory diseases. The core of MediciNova Inc.'s business model is the research and development of new compounds. Through targeted research and clinical trials, new compounds are developed and subsequently approved for the American and international markets. Currently, several drugs of the company are still in the clinical phase of research and development, including those for the treatment of neurodegenerative diseases and asthma. However, the company's most well-known product is the drug Ibudilast (MN-166), which was developed for the treatment of multiple sclerosis and neuronal damage. Another important pillar of MediciNova Inc.'s business model is the distribution of the developed drugs. The company works closely with other biotech companies and pharmaceutical companies to optimize the marketing and distribution of the drugs. In another business area, the company offers innovative solutions for drug delivery technology. Medications are specially formulated to achieve optimal effectiveness and reduce negative effects on the body. This technology can also be utilized by other pharmaceutical companies and serves as an additional source of income for the company. In summary, MediciNova Inc. is actively searching for innovative therapies for unmet medical needs and has a comprehensive business model that spans from research and development to the distribution of developed drugs and innovative solutions for drug delivery technology. The company has established a reputable presence in the industry and is considered an important player in the biotech sector.

What is the MediciNova dividend?

MediciNova pays a dividend of 0 USD distributed over payouts per year.

How often does MediciNova pay dividends?

The dividend cannot currently be calculated for MediciNova or the company does not pay out a dividend.

What is the MediciNova ISIN?

The ISIN of MediciNova is US58468P2065.

What is the MediciNova WKN?

The WKN of MediciNova is A0LF3U.

What is the MediciNova ticker?

The ticker of MediciNova is MNOV.

How much dividend does MediciNova pay?

Over the past 12 months, MediciNova paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, MediciNova is expected to pay a dividend of 0 USD.

What is the dividend yield of MediciNova?

The current dividend yield of MediciNova is .

When does MediciNova pay dividends?

MediciNova pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of MediciNova?

MediciNova paid dividends every year for the past 0 years.

What is the dividend of MediciNova?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is MediciNova located?

MediciNova is assigned to the 'Health' sector.

Wann musste ich die Aktien von MediciNova kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of MediciNova from 11/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/9/2024.

When did MediciNova pay the last dividend?

The last dividend was paid out on 11/9/2024.

What was the dividend of MediciNova in the year 2023?

In the year 2023, MediciNova distributed 0 USD as dividends.

In which currency does MediciNova pay out the dividend?

The dividends of MediciNova are distributed in USD.

All fundamentals about MediciNova

Our stock analysis for MediciNova Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MediciNova Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.